Canine hemangiosarcoma treated with standard chemotherapy and minocycline.
Standard treatments for canine hemangiosarcoma include surgery and chemotherapy with doxorubicin, but in spite of treatment most dogs with this disease die within 6 months of diagnosis. Tumor growth and metastasis are angiogenesis dependent. Antiangiogenic drugs such as minocycline may provide therapeutic benefits in cancer patients. The purpose of this prospective study was to evaluate the efficacy of chemotherapy with doxorubicin and minocycline, an antiangiogenic agent, in dogs with hemangiosarcoma. Eighteen dogs with histologically confirmed hemangiosarcoma of any stage were treated with doxorubicin, cyclophosphamide, and minocycline. Complete staging was performed before and during the treatment period to assess remission status and response to therapy. No statistically significant difference was found in survival between the dogs treated with chemotherapy and minocycline, and historical controls consisting of dogs that received chemotherapy alone. Postmortem examination revealed widespread metastasis, suggesting that minocycline is ineffective as a single antiangiogenic agent in canine hemangiosarcoma.
Sorenmo
K
K
Department of Clinical Studies and Pathobiology, Veterinary Hospital of the University of Pennsylvania, Philadelphia 19104, USA. Karins@vet.upenn.edu
Duda
L
L
Barber
L
L
Cronin
K
K
Sammarco
C
C
Usborne
A
A
Goldschmidt
M
M
Shofer
F
F
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000662:veterinary*; D008297:Male; D008911:Minocycline / Q000627:therapeutic use*; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D011446:Prospective Studies; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D013160:Splenic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D016019:Survival Analysis
D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D008911:Minocycline